The pharmacology of HIV drug resistance

American Journal of Pharmaceutical Education

Volumn 70, Issue 5, 2006, Pages

  Zdanowicz, Martin M ^a,b  

^a South University   (United States)

^b SOUTHERN UNIVERSITY   (United States)

Author keywords

Drug resistance; HIV pharmacotherapy; Human immunodeficiency virus; Pharmacology

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; EDUCATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EDUCATION, PHARMACY; HIV INFECTIONS; HIV-1; HUMANS;

EID: 33750808446     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/aj7005100     Document Type: Review

References (31)

1. Tobin N, FrenkelL. Human immunodeficiency virus drug susceptibility and resistance testing. Pediatr Infect Dis J. 2002;21:668-83.
2. Richman DR, Morton SC, Wrin T, Hellman N, Berry S, Shapiro MF, Bozette S. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-402.
3. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1-infected persons in 10 U.S. cities. J Infect Dis. 2004;189:2174-80.
4. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science. 1988;242:1168-71.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-6.
6. Marinez-Picardo J, DePasquale MP, Kartsonis N, et al. Antiretroviral resistance during successful therapy of HIV type I infection. Proc Natl Acad Sci. 2000;97:10948-53.
7. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-35.
8. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5.
9. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004;54:333-40.
10. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 2001;15:1701-06.
11. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virology. 2001;65:445-8.
12. Yeh RW, Coen DM. Pharmacology of viral replication. In: Golan DE, ed. Principles of Pharmacology. New York: Lippincott Williams & Wilkins; 2005:545-64.
13. CNN Health. Drug-resistant HIV strain alarms officials. Available at http://edition.cnn.com/2005/HEALTH/conditions/02/11/drug.resistant.aids/. Accessed January 10, 2006.
14. Funesti J, Stacy F. HIV drug resistance and nursing practice. Am J Nursing. 2001;101:30-4.
15. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type I: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2003;37:113-28.
16. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-93.
17. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-99.
18. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79.
19. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-50.
20. Sax PE, Islam R, Walenasky RP, et al. Should resistance testing be performed for treatment-naïve HIV infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41:1316-23.
21. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88.
22. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2004;36:967-71.
23. Cahn P, Vibhagool A, Schecter M, et al. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacaviror indinavir-based triple combination HAART also containing lamivudine/zidovudine. Curr Med Res Opin. 2004;20:1115-23.
24. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, Kaplan AH. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41:315-22.
25. World Health Organization. Drug resistance, HIV/ AIDS. Available at http://www.who.int/drugresistance/hivaids/en/. Accessed January 11, 2006.
26. Marks K, Gulick RM. New antiretroviral agents for the treatment of HIV infection. HIV/AIDS Rep. 2004;1:82-8.
27. Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery and mechanism of action. Antisense Nucleic Acid Drug Dev. 2002;12:103-28.
28. Kurreck J. Antisense technologies. Eur J Biochem. 2003;270:1628-44.
29. Schubert U, Ott DE, Chertova EN, et al. PNAS. Proteasome inhibition interferes with Gag polyprotein processing, release and maturation of HIV-1 and HIV-2.
30. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-8.
31. Veazey RS, Klasse PJ, Ketas TJ. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency infection. J Exp Med. 2003;17:1551-62.